Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H G Prentice

Showing results (31-40 of 299) with videos related to

Pageof 30
Sort By:
The Journal of Antimicrobial Chemotherapy|June 1, 1985
Aminoglycoside toxicityP Noone, H G Prentice, R J Sage
Bone Marrow Transplantation|January 1, 1989
T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way aheadH G Prentice, M K Brenner, D Gottlieb
Investigational New Drugs|January 1, 1985
Sequential studies on the role of mitoxantrone in the treatment of acute leukemiaH G Prentice, J Z Wimperis, G Robbins
BMJ (Clinical Research Ed.)|August 23, 1997
Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. Combining different antifungal strategies in same systematic review is inappropriateC C Kibbler, R Manuel, H G Prentice
Acta Oncologica (Stockholm, Sweden)|January 1, 1988
Allogeneic bone marrow transplantation. Recent developments and the potential expansion of the donor poolH G Prentice, M K Brenner, M McGovern
Journal of Clinical Microbiology|October 1, 1988
Antithrombin III in the diagnosis of infection in febrile neutropenic patientsC C Kibbler, H G Prentice, P Noone
Hematology (Amsterdam, Netherlands)|July 14, 2016
Understanding the Graft-Versus-Leukaemia ReactionM W Lowdell, R Craston, H G Prentice
Clinics in Haematology|October 1, 1984
Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patientsR Saral, W H Burns, H G Prentice
Haematologia|January 1, 1986
The use of monoclonal antibodies in graft versus host disease preventionM K Brenner, J P Grob, H G Prentice
Bone Marrow Transplantation|June 18, 1999
Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxisM B Koh, H G Prentice, M W Lowdell
Pageof 30

Showing results (31-40 of 299) with videos related to

Sort By:
Pageof 30
The Journal of Antimicrobial Chemotherapy|June 1, 1985
Aminoglycoside toxicityP Noone, H G Prentice, R J Sage
Bone Marrow Transplantation|January 1, 1989
T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way aheadH G Prentice, M K Brenner, D Gottlieb
Investigational New Drugs|January 1, 1985
Sequential studies on the role of mitoxantrone in the treatment of acute leukemiaH G Prentice, J Z Wimperis, G Robbins
BMJ (Clinical Research Ed.)|August 23, 1997
Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. Combining different antifungal strategies in same systematic review is inappropriateC C Kibbler, R Manuel, H G Prentice
Acta Oncologica (Stockholm, Sweden)|January 1, 1988
Allogeneic bone marrow transplantation. Recent developments and the potential expansion of the donor poolH G Prentice, M K Brenner, M McGovern
Journal of Clinical Microbiology|October 1, 1988
Antithrombin III in the diagnosis of infection in febrile neutropenic patientsC C Kibbler, H G Prentice, P Noone
Hematology (Amsterdam, Netherlands)|July 14, 2016
Understanding the Graft-Versus-Leukaemia ReactionM W Lowdell, R Craston, H G Prentice
Clinics in Haematology|October 1, 1984
Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patientsR Saral, W H Burns, H G Prentice
Haematologia|January 1, 1986
The use of monoclonal antibodies in graft versus host disease preventionM K Brenner, J P Grob, H G Prentice
Bone Marrow Transplantation|June 18, 1999
Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxisM B Koh, H G Prentice, M W Lowdell
Pageof 30